Tissue selectivity of hydroxymethylglutaryl coenzyme a (HMG CoA) reductase inhibitors

Pharmacology and Therapeutics

Volumn 60, Issue 3, 1993, Pages 431-459

  Sirtori, Cesare R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cholesterol; compactin; endocrine tissue; HMG CoaA reductase inhibitors; hypercholesterolemia; lens; lovastatin; muscle; pravastatin; simvastatin; tissue selectivity

Indexed keywords

COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANIMAL TISSUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DRUG ABSORPTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; HYDROPHILICITY; LIPOPHILICITY; LIVER; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMAN; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; PRAVASTATIN; RHABDOMYOLYSIS; RISK FACTORS; SIMVASTATIN; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0027819738     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(93)90031-8     Document Type: Review

References (125)

1. XbaI and c/g polymorphisms of the apolipoprotein B gene locus are associated with serum cholesterol and LDL-cholesterol levels in Finland
2. Effects of HMG CoA reductase inhibitors on cholesterol synthesis
3. Mevinolin: a highly potent competitive inhibitor of HMG-CoA reductase and a cholesterol-lowering and a cholesterol-lowering agent
4. Über die Veränderungen der Kaninchenaorta bei experimenteller Cholesterinsteatose
5. Simvastatin
6. Pravastatib sodium (CS-514), a novel cholesterol-lowering agent which inhibits HMG-CoA reductase
7. Effects of low density lipoproteins and mevinolin on sympathetic responsiveness in cultured chick atrial cells
8. Stereospecificity of the chloride ion channel: the action of chiral clofibric acid and analogues
9. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes
10. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration with selected HMG-CoA reducase inhibitors
11. Long-term safety and efficacy profile of simvastatin
12. Human lipoprotein molecular biology
13. A receptor-mediated pathway for cholesterol homeostasis
14. Sterol biosynthesis by the ocular lens in the rat during postnatal development
15. 22-Hydroxycholesterol derivatives as HMG CoA reductase suppressors and serum cholesterol lowering agents
16. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels
17. HMG-CoA reductase inhibitors differently affect membrane electric characteristics of rat skeletal muscle fibres
18. Poor response to simvastatin in familial defective apolipoprotein B-100
19. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes
20. CNS-related side effects with metoprolol and atenolol
21. Cholesterol distribution in the bulk tissues of man: variation with age
22. Regulation of cholesterol metabolism (First of three parts)
23. Regulation of cholesterol metabolism (Second of three parts)
24. Regulation of cholesterol metabolism (Third of three parts)
25. Carrier-mediated transport of ouabain in isolated hepatocytes
26. Clofibrate-induced myotonia in the rat
27. Hyperkalaemia during treatment with HMG-CoA reductase inhibitor
28. Relationship of cholesterogenesis to DNA synthesis and proliferation by lens epithelial cells in culture
29. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
30. Inhibition of cholesterol synthesis in in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase
31. Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of 17α-hydroxylase: C-17, 20-lyase complex
32. Biotransformation of pravastatin sodium in humans
33. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (Mevinolin) or neomycin
34. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks
35. The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia
36. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers
37. Specific restriction of cholesterol from cortical lens gap junctional membrane in the U18666A cataract
38. The transport of bile acids in liver cells
39. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts
40. Effect of 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibition on gut mucosa
41. Drug kinetics and hepatic blood flow
42. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo
43. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors
44. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors
45. The effect of acute hypercholesterolemia on myocaridal infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion
46. Cell proliferation in human coronary arteries
47. Relationship of epidermal lipogenesis to cutaneous barrier function
48. HMG-CoA reductase inhibotors for treatment of hypercholesterolemia
49. Influence of mevinolin on metabolism of low density lipoproteins im primary moderate hypercholesterolemia
50. The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands
51. +/bile acid contransporter in Xenopus laevis oocytes
52. Effects of low density lipoproteins and mevinolin on cholesterol control and muscarinic cholinergic responsiveness in cultured chick atriall cells
53. HMG CoA reductase activity of lens epithelial cells: compared with true rates of sterol synthesis
54. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treratment of hypercholesterolemia
55. Seroconversion from hepatitis Be antigen to antibody in chronic type B hepatitis
56. Hypopocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100
57. Cell cycle-specific effects of lovastatin
58. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens
59. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase
60. The inheritance of essential familial hypercholesterolemia
61. Cholesterol is required for sectrion of very low density lipoprotein by the rat liver
62. Studies on the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the rodent forestomach
63. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
64. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture
65. Toxicity of the HMG-coenzyme A reductase inhibotor, lovastatin, to rabbits
66. Regulatory role for hepatic low-density lipoprotein receptors in vivo in the dog
67. Forestomach carcinogens: possible mechanisms of action
68. Hypolipidemic effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
69. Two systems are involved in the sulfobromophthalein uptake by rat liver cells: one is hard is shared with bile salts
70. 2 stimulation of progesterone secretion in culturerd placental trophoblast
71. Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the humans lens after 48 weeks of treatment with lovastatin
72. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway
73. Cataracts in patients treated with triparanol
74. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low-density lipoprotein receptor in livers of hasmters and rabbits
75. Differential transport of pravastatin and lovastatin by hepatocytes abd fibroblasts
76. Cholestatic jaundice associated with lovastatin therapy
77. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia
78. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens
79. Cardiovascular effects of acute hypercholesterolemia in rabbits
80. Pharmacokinetics and pharmacodynamics aof pravastatin alone and with cholestyramine in hypercholesterolemia
81. Comparative pharmacokinetics of lovastatin, sinvastatin and pravastatin in humans
82. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
83. Experimental evaluation of the effects of pravastatin on the electrophysiological parameters of rat skeletal muscle
84. 100: clinical characteristics of 54 cases
85. Lovastatin-induced hepatitis
86. 2+ channel activity and uncouples excitation from contraction in cardiac cells in culture
87. Apolipoprotein B gene polymorphisms are associated with lipid levels in men of South Asian descent
88. HMG CoA reductase: a negatively regulated gene with unusual promoter and 5′ untranslated regions
89. Clofibrate-induced muscular syndrome
90. Effects of apoprotein E polymorphism on serum lipoprotein concentration
91. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance
92. Prevention of restenosis by lovastatin after successful coronary angioplasty
93. Letter to Editor: HMG-CoA reductase inhibitors for hypercholesterolemia
94. Pravastatin-associated inflammatory myopathy
95. ++ channel blockers
96. Hydrophilicity and the differential pharmacology of pravastatin
97. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
98. Expanded clinical evaluation of lovastatin (EXCEL) study results
99. Possible involvement of 3-hydroxymethylglutaryl-CoA reductase in determining the side-chain length of ubiquinone in rat heart
100. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
101. Pharmacology amd mechanism of action of the new HMG-CoA reductase inhibitors
102. Tolerability of fibric acids, comparative data and biochemical bases
103. Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
104. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity
105. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies
106. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat
107. ++ influx induced by IGF-1 in FRTL-5 cells
108. Effects of exercise and lovastatin on serum creatine kinase activity
109. Efficacy and long-term adverse effects of lovastatin
110. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers
111. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
112. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effecton varioys animal species
113. Cholesterol metabolism and excretion
114. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia
115. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins
116. Effects of lovastatin and pravastatin on sleep stages
117. Biotransformatio of lovastatin I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse
118. Biotranformation of lovastatin. IV Identification of cytochrome P450 3 A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
119. HNG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes
120. Intestinal transport of bile-acids
121. Influence of dietary cholesterol on cholesterol metabolism
122. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health
123. Therapeutic effects of ML-236B in primary hypercholesterolemia
124. Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter
125. Modified somatostatins as inhibitors of a multispecific transport-system for bile-acids and phallotoxins in isolated hepatocytes